Innovent Bio (OTCMKTS:IVBXF) shares traded up 9.1% during mid-day trading on Friday . The company traded as high as $6.00 and last traded at $6.00, 1,050 shares changed hands during mid-day trading. A decline of 93% from the average session volume of 14,572 shares. The stock had previously closed at $5.50.
Separately, JPMorgan Chase & Co. cut Innovent Bio from an “overweight” rating to a “neutral” rating in a research report on Wednesday, July 8th.
About Innovent Bio (OTCMKTS:IVBXF)
Innovent Biologics, Inc operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma.
Featured Article: How does quantitative easing work?
Receive News & Ratings for Innovent Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Bio and related companies with MarketBeat.com's FREE daily email newsletter.